The role of FBXW7 , a cell-cycle regulator, as a predictive marker of recurrence of gastrointestinal stromal tumors
ConclusionFBXW7 is a potential predictive marker of recurrence after curative resection of GISTs. FBXW7 expression may help identify patients benefitting from adjuvant therapy more precisely compared with a conventional risk stratification model.
ConclusionsOur data suggest that WEE1 plays a pivotal role in GIST proliferation. WEE1 inhibition could promote KIT autophagic degradation and, therefore, targeting WEE1 might represent a novel strategy for GIST therapies.
It is important to accurately differentiate gastrointestinal stromal tumors (GISTs) from other gastric submucosal tumors (SMTs) because the difference of their malignant potential may affect the selection of therapeutic strategy. However, it is often difficult for small SMTs to be diagnosed for GISTs by histology. National Comprehensive Cancer Network sarcoma guidelines suggest that SMTs
ConclusionsCystic GISTs is a relatively indolent subset of GISTs with favorable prognoses and adjuvant imatinib should be a prudent consideration.
CONCLUSIONS: GISTs had a wide spectrum of presentation, and immunohistopathological features with organ sparing resection were conceivable in maximum. Nuclear pleomorphism may be considered as an important variable to predict recurrence in addition to malignant potential of tumors.
CONCLUSIONS: In localized GISTs R0 surgical resection is the standard therapy as it leads to excellent outcomes. Our findings suggest that all the three classifications considered are adequate to achieve a correct prognostic evaluation. KEY WORDS: GIST, Prognostic factors, Prognostic models. PMID: 30942768 [PubMed - in process]
are subdivided into those of epithelial and stromal origin. Malignant tumours are more common than benign, with adenocarcinomas being the most common type of malignancy. Rarer gastric malignancies include gastrointestinal stromal tumours (GISTs), lymphomas and neuro-endocrine tumours. Gastric cancer is the sixth most common cancer in Europe and the fourth most common cause of cancer death. Multidisciplinary treatment planning is an essential part of management of these cancers. The only curative treatment option is surgical resection, although this is usually accompanied by perioperative chemotherapy or adjuvant chemoradiotherapy.
Conclusion: Our analysis supports treating GIST patients with neoadjuvant imatinib, which demonstrated favorable long-term results of combined therapy. However, careful monitoring of complications is necessary. The optimal duration of neoadjuvant imatinib use before surgical intervention is, on average, 6.1 months.
Abstract BACKGROUND: Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal tumor type in the gastrointestinal system. Presently, various classification systems to prognosticate GISTs have been proposed. AIM: To evaluate the application value of four different risk stratification systems for GISTs. METHODS: Patients who were diagnosed with GISTs and underwent surgical resection at four hospitals from 1998 to 2015 were identified from a database. Risk of recurrence was stratified by the modified National Institute of Health (NIH) criteria, the Armed Forces Institute of Pathology (AFIP) cr...
Conclusion: EGISTs are one of the rare differentials for spindle cell lesions outside the GIT. Although both markers stain positive, DOG1 showed higher score with epithelioid GISTs.
ConclusionsThe scoring system based on the information of digital image analysis is useful in predicting GISTs in case of GMTs that are 2 –5 cm in size.